Related references
Note: Only part of the references are listed.Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease
Xiao Chen et al.
BLOOD (2009)
Cutting edge:: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+ CD25- T cells
Sabine Dominitzki et al.
JOURNAL OF IMMUNOLOGY (2007)
TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets
M. Pyzik et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Recent developments in renal cell cancer immunotherapy
P. J. Wysocki et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The descent of memory T-cell subsets
Leo Lefrancois et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice
Piotr J. Wysocki et al.
CLINICAL CANCER RESEARCH (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Restoration of expression of transforming growth factor-β type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2′-deoxycytidine
Q Zhang et al.
LIFE SCIENCES (2005)
Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model
I Kausch et al.
EUROPEAN UROLOGY (2004)
Human cancer gene therapy with cytokine gene-modified cells
PJ Wysocki et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
WJ Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Similarities and differences in CD4+ and CD8+ effector and memory T cell generation
RA Seder et al.
NATURE IMMUNOLOGY (2003)
Lineage relationship and protective immunity of memory CD8 T cell subsets
EJ Wherry et al.
NATURE IMMUNOLOGY (2003)
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
SR Scheffer et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Genetically modified dendritic cells - a new, promising cancer treatment strategy?
PJ Wysocki et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Immunotherapeutic potential of whole tumour cells
S Ward et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
CD4+CD25+ suppressor T cells:: More questions than answers
EM Shevach
NATURE REVIEWS IMMUNOLOGY (2002)
Murine renal cell carcinoma: evaluation of a dendritic-cell tumour vaccine
F Chagnon et al.
BJU INTERNATIONAL (2001)
Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16
DW Kowalczyk et al.
VACCINE (2001)
Behavior of murine renal carcinoma cells crown in ectopic or orthotopic sites in syngeneic mice
KS Ahn et al.
TUMOR BIOLOGY (2001)
The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells
S Özbek et al.
ONCOGENE (2001)
Cytokine-secreting tumor cell vaccines
N Mach et al.
CURRENT OPINION IN IMMUNOLOGY (2000)
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells
ZH Qin et al.
IMMUNITY (2000)
Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon renal cell carcinoma
SK Mendiratta et al.
HUMAN GENE THERAPY (2000)
Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration
I Hara et al.
CANCER GENE THERAPY (2000)
Share Paper
